Health Care • Medical/Dental Instruments
$2.38 ▼ -0.06
(-2.46%)
MKT CAP: $477.2M • VOL: 95.2K
52W L $2 52W H $8
SSII // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $42.5M | $20.6M | $5.9M |
| YoY Revenue Growth % | +105.7% | +251.5% | — |
| Gross Profit | $19.5M | $8.5M | — |
| Gross Margin % | 46.0% | 40.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.2M | -$19.0M | -$20.3M |
| Operating Margin % | -19.3% | -80.0% | -80.0% |
| Net Income (GAAP) | -$12.1M | -$19.2M | -$20.9M |
| EBITDA (Normalized) | -$5.3M | -$18.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.5M | -$9.5M | -$15.4M |
| Capital Expenditures (CapEx) | $3.7M | $661.5K | — |
| Free Cash Flow (FCF) | -$22.2M | -$10.2M | -$15.4M |
| FCF Margin % | -52.3% | -49.2% | -80.0% |
| Return on Invested Capital (ROIC %) | -18.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.2M | $466.5K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $38.2M | $13.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SSII.